Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
NCT05368402 · Dompé Farmaceutici S.p.A · PHASE2 · terminated · last registry update 2025-02-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “low recruitment rate” | – | Registry record, Dompé Farmaceutici S.p.A |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-14Results posted on the registry: Dompé Farmaceutici S.p.A, Ladarixin (NCT04899271)
- 2025-05-14Also stopped (terminated): Dompé Farmaceutici S.p.A, Ladarixin (NCT04899271)
- 2025-01-07Also stopped (terminated): Dompé Farmaceutici S.p.A, Reparixin (NCT03031470)
- 2024-12-11Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin (NCT03031470)
- 2024-12-11Results posted on the registry: Dompé Farmaceutici S.p.A, Repertaxin (NCT00224406)
- 2024-06-13Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin (NCT04878055)
- 2024-04-30Also stopped (withdrawn): Dompé Farmaceutici S.p.A, Reparixin + Placebo (NCT05212701)
- 2024-03-29Also stopped (withdrawn): NYU Langone Health, Sotorasib + Ladarixin (NCT05815186)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision